Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 5/20 | 0.50 |
| ▸ | KDM1A | O60341 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594786 | 1.00 | NPY5R (0.53) | NPY5RTACR1KDM1AMAOAMAOB | |
| SCHEMBL1594787 | 1.00 | NPY5R (0.53) | NPY5RTACR1KDM1AMAOAMAOB | |
| Bromide SCHEMBL1593620 | 0.99 | NPY5R (0.52) | NPY5RTACR1KDM1AMAOAMAOB | |
| Bromide SCHEMBL1593618 | 0.99 | NPY5R (0.52) | NPY5RTACR1KDM1AMAOAMAOB | |
| Bromide SCHEMBL1593617 | 0.99 | NPY5R (0.52) | NPY5RTACR1KDM1AMAOAMAOB | |
| SCHEMBL4287875 | 0.92 | NPY5R (0.48) | NPY5RTACR1KDM1AMAOAMAOB | |
| SCHEMBL4292822 | 0.92 | NPY5R (0.48) | NPY5RTACR1KDM1AMAOAMAOB | |
| SCHEMBL4287872 | 0.92 | NPY5R (0.48) | NPY5RTACR1KDM1AMAOAMAOB | |
| SCHEMBL4292821 | 0.92 | NPY5R (0.48) | NPY5RTACR1KDM1AMAOAMAOB | |
| SCHEMBL4287876 | 0.92 | NPY5R (0.48) | NPY5RTACR1KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1119543-B1 | N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | claimed |
| US-6201025-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-03-13 | — | — | US | claimed |
| US-7919329-B2 | Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2050460-A1 | PYY and agonists thereof for modification of feeding behaviour | Imperial Innovations Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| US-7459432-B2 | Modification of feeding behavior | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080213803-A1 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH & SCIENCE UNIVERSITY | 2008-09-04 | — | — | US | disclosed |
| EP-1585956-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | Oregon Health and Science University (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-11 | — | — | US | disclosed |
| US-20050015820-A1 | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | disclosed |
| EP-1119543-B1 | N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003027637-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6201025-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NPY4R, NPY2R, NPY1R | NPY5R 4/4885TACR1 135/4885KDM1A 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.